2026年2月23日 美国东部时间晚上8:15 / 路透社 / 艾哈迈德·阿布勒内因报道
华盛顿，2月23日（路透社） – 美国食品药品监督管理局（FDA）局长马蒂·马卡里周一为其机构在mRNA疫苗方面的立场和记录进行了辩护。此前几天，FDA改变了立场，同意审查Moderna的流感疫苗。
马卡里表示，FDA支持mRNA疫苗，但纳税人不应为此买单。他提及了美国卫生部门去年采取的几项削减mRNA疫苗研究资金的举措。他在一个宣布FDA提议的加速罕见病基因疗法审批框架的活动上发表了上述言论。
订阅路透社健康动态通讯，及时了解最新的医学突破和医疗趋势。点击此处订阅。
（注：原文此处显示”节点运行失败”，未影响主要内容）
当被问及在支持基因疗法中使用的基因组编辑技术与不支持mRNA疫苗之间是否存在矛盾时，马卡里表示：”认为我们不支持mRNA疫苗将是一个相当牵强的说法。在我履职初期，我们已经批准了两种mRNA疫苗。”
FDA已批准两种针对呼吸道合胞病毒（RSV）的信使核糖核酸（mRNA）疫苗——一种来自Moderna，另一种来自葛兰素史克（GSK）。
马卡里补充道：”我很乐意看到mRNA在治疗癌症和多种疾病方面的数据。”
Moderna和默克也在合作开发一种个性化疗法，该疗法结合了mRNA技术和默克的免疫疗法药物Keytruda（帕博利珠单抗）来对抗癌症。
马卡里称美国因资金问题削减mRNA疫苗资助
马卡里为美国卫生与公众服务部（HHS）去年8月决定终止其生物医学研究部门下的mRNA疫苗开发活动进行了辩护。当时，HHS部长小罗伯特·F·肯尼迪（Robert F. Kennedy Jr.）——一位长期反疫苗活动人士——声称”数据表明这些疫苗无法有效预防新冠和流感等上呼吸道感染”，尽管有相反的科学证据。
此前，HHS在5月终止了为Moderna开发针对禽流感等具有大流行潜力病原体的mRNA疫苗提供的超过7亿美元资金，该疫情当时已导致奶牛大规模爆发并感染工人。
马卡里表示，该部门削减mRNA疫苗开发资金是因为生产这些药物的公司能够承担自己的研究费用。
“HHS曾为mRNA技术提供资金。这些资金被转向了其他项目，我来告诉大家原因。这不是因为我们不相信mRNA技术，而是因为生产mRNA疫苗的公司已经赚了超过500亿美元，他们能够资助自己的研究。这不必以美国纳税人的利益为代价。”马卡里说道。
Moderna以及辉瑞和BioNTech SE在政府应对新冠疫情的工作中生产了mRNA新冠疫苗。辉瑞/BioNTech的疫苗是自筹资金，而Moderna则使用了政府资金。
马卡里表示，政府应该资助那些资金不足的领域的研究，例如”定制化疾病和罕见病——那些被现代医学忽视的疾病”。
艾哈迈德·阿布勒内因在华盛顿报道；朱莉·斯滕胡伊森在芝加哥补充报道；卡罗琳·休默和马修·刘易斯编辑。
US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost
February 23, 2026 8:15 PM UTC / Reuters / By Ahmed Aboulenein
WASHINGTON, Feb 23 (Reuters) – U.S. Food and Drug Administration Commissioner Marty Makary on Monday defended his agency’s position and record on mRNA vaccines, days after it changed course and agreed to review a Moderna flu vaccine.
The FDA supports mRNA vaccines, but taxpayers should not foot the bill, Makary said, referring to several Health Department moves last year to cut funding for mRNA vaccine research. He spoke at an event announcing an FDA-proposed framework to speed the approval of gene therapies to treat rare diseases.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
节点运行失败
Asked if there was a contradiction between embracing genome editing, a technique used in gene therapy, but not mRNA vaccines, Makary said, “I think that would be quite a stretch to say we’re not embracing mRNA vaccines. We’ve approved two mRNA vaccines at the beginning of my time.”
The FDA has approved two messenger RNA vaccines against RSV – one from Moderna and the other from GSK.
“I would love to see the data on mRNA helping patients with cancer and a number of conditions,” Makary added.
Moderna and Merck are also working on a personalized treatment that uses mRNA technology in combination with Merck’s immunotherapy Keytruda to fight cancer.
MAKARY SAYS U.S. DEFUNDED MRNA OVER MONEY
Makary defended the U.S. Department of Health and Human Services’ August decision to wind down mRNA vaccine development activities under its biomedical research unit. At the time, Secretary of Health and Human Services Robert F. Kennedy Jr., a longtime anti-vaccine activist, said “the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu,” despite scientific evidence to the contrary.
That followed the HHS’s termination in May of more than $700 million in funding for Moderna to develop an mRNA vaccine to protect against pathogens with pandemic potential including bird flu, which had touched off a major outbreak in dairy cows that was infecting workers.
Makary said the department cut funding for the development of mRNA vaccines because companies that make the drugs can afford their own research.
“There was funding for mRNA technology at HHS. That funding was pivoted to other causes, and I’ll tell you why. It’s not because we don’t believe in mRNA technology. It’s because the companies that made mRNA vaccines made over $50 billion, they can fund their own research. It doesn’t have to be on the backs of American taxpayers,” said Makary.
Moderna, as well as Pfizer and BioNTech SE , made mRNA COVID shots as part of the government’s COVID pandemic effort. The Pfizer/BioNTech shot was self-funded while Moderna used government funding.
Makary said the government should fund research in areas that are underfunded, such as “bespoke conditions and rare diseases, conditions that have been in the blind spots of modern medicine.”
Reporting by Ahmed Aboulenein in Washington; Additional reporting by Julie Steenhuysen in Chicago; Editing by Caroline Humer and Matthew Lewis
发表回复